NCT02637323View on ClinicalTrials.gov

Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Osteoarthritis of the Knee
Interventions
DRUG

FX006 32 mg

Single 5 mL IA injection

DRUG

TCA IR 40

Single 1 mL IA injection

Trial Locations (4)

16635

Duncansville

33012

Hialeah

91303

Canoga Park

92103

San Diego

Sponsors
All Listed Sponsors
lead

Pacira Pharmaceuticals, Inc

INDUSTRY

NCT02637323 - Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee | Biotech Hunter | Biotech Hunter